Back to Search
Start Over
Rare variants in CAPN2 increase risk for isolated hypoplastic left heart syndrome.
- Source :
-
HGG advances [HGG Adv] 2023 Aug 12; Vol. 4 (4), pp. 100232. Date of Electronic Publication: 2023 Aug 12 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect (CHD) characterized by hypoplasia of the left ventricle and aorta along with stenosis or atresia of the aortic and mitral valves. HLHS represents only ∼4%-8% of all CHDs but accounts for ∼25% of deaths. HLHS is an isolated defect (i.e., iHLHS) in 70% of families, the vast majority of which are simplex. Despite intense investigation, the genetic basis of iHLHS remains largely unknown. We performed exome sequencing on 331 families with iHLHS aggregated from four independent cohorts. A Mendelian-model-based analysis demonstrated that iHLHS was not due to single, large-effect alleles in genes previously reported to underlie iHLHS or CHD in >90% of families in this cohort. Gene-based association testing identified increased risk for iHLHS associated with variation in CAPN2 (p = 1.8 × 10 <superscript>-5</superscript> ), encoding a protein involved in functional adhesion. Functional validation studies in a vertebrate animal model ( Xenopus laevis ) confirmed CAPN2 is essential for cardiac ventricle morphogenesis and that in vivo loss of calpain function causes hypoplastic ventricle phenotypes and suggest that human CAPN2 <superscript>707C>T</superscript> and CAPN2 <superscript>1112C>T</superscript> variants, each found in multiple individuals with iHLHS, are hypomorphic alleles. Collectively, our findings show that iHLHS is typically not a Mendelian condition, demonstrate that CAPN2 variants increase risk of iHLHS, and identify a novel pathway involved in HLHS pathogenesis.<br />Competing Interests: M.J.B. and J.X.C. are the editor-in-chief and deputy editor, respectively, of Human Genetics and Genomics Advances and were recused from the editorial handling of this article. J.J.W. is an employee and shareholder of Invitae. M.J.B. is chair of the Scientific Advisory Board of GeneDx. S.M. is on the Hypertrophic Cardiomyopathy Advisory Board of Bristol-Myers Squibb.<br /> (© 2023 The Author(s).)
Details
- Language :
- English
- ISSN :
- 2666-2477
- Volume :
- 4
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- HGG advances
- Publication Type :
- Academic Journal
- Accession number :
- 37663545
- Full Text :
- https://doi.org/10.1016/j.xhgg.2023.100232